Sylvia Adams, MD | Authors


Phase II Results for Pembrolizumab Monotherapy in Metastatic TNBC

June 20, 2017

Sylvia Adams, MD, associate professor, Department of Medicine, NYU Langone Medical Center, discusses phase II results from cohort A of the KEYNOTE-086 trial, which explored pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer.

Dr. Sylvia Adams on Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer

November 12, 2015

Sylvia Adams, MD, medical oncologist, NYU Langone Medical Center, talks about the the importance of tumor-infiltrating lymphocytes (TILS) and how they can mark which patients will respond to immunotherapy use in triple negative breast cancer (TNBC). She discussed this topic at the recent Chemotherapy Foundation Symposium.